Liraglutide and semaglutide reduce alcohol intake, cutting it by nearly two-thirds within four months of treatment.

Patients taking liraglutide or semaglutide for weight loss report their alcohol intake dropping with the pounds-by as much as ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

New study finds weight loss jabs not only help tackle obesity but may significantly reduce alcohol use, offering wide health ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

New research presented at the European Congress on Obesity (ECO 2025) and published in the journal Diabetes, Obesity and ...

People taking semaglutide or liraglutide reduced their alcohol consumption by two-thirds within four months, according to results recently published in the journal Diabetes, Obesity and Metabolism.

The study showed that Glucagon-like peptide-1 (GLP-1) analogues — drugs developed to treat obesity — likely curb alcohol ...

While GLP-1 receptor agonists and bariatric surgery offer significant metabolic benefits, experts caution that rapid weight ...

Essentially, Ozempic and Wegovy are brand names for semaglutide, which is in the GLP-1 receptor agonist (GLP-1RA) drug class.

Weight loss jabs could help reduce alcohol consumption in obese people by around two thirds, a new study suggests.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal ...